Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

Can bio foundation models solve the most critical therapeutics problem, predicting which patients will respond to a therapy? Today, we share more details in a white paper on our recently reported results using NOETIK TARIO-2 to predict responders in an actual clinical trial setting with Agenus.

Ron Alfa

7,002 subscribers

17,153 views • 19 days ago •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

🔬 Training Transformers to solve 95% failure rate of Cancer Trials the AI for Science pod is back with Ron Alfa, CEO of NOETIK, and Daniel Bear, VP Research at Noetik, explaining exactly how their team of top AI x Bio researchers and engineers (shoutout owl) will use AI to cure cancer, by focusing on key bottlenecks like patient selection, and training large cancer foundation models like TARIO-2, an autoregressive transformer trained on one of the largest sets of tumor spatial transcriptomics datasets in the world... which first required years of blind faith in collecting good data to even get going:

🔬 Training Transformers to solve 95% failure rate of Cancer Trials the AI for Science pod is back with Ron Alfa, CEO of NOETIK, and Daniel Bear, VP Research at Noetik, explaining exactly how their team of top AI x Bio researchers and engineers (shoutout owl) will use AI to cure cancer, by focusing on key bottlenecks like patient selection, and training large cancer foundation models like TARIO-2, an autoregressive transformer trained on one of the largest sets of tumor spatial transcriptomics datasets in the world... which first required years of blind faith in collecting good data to even get going:

Latent.Space

18,260 views • 2 months ago

Scientists say the first clinical trial to test whether adults - with a severe allergy to peanuts - can safely tolerate them, has had positive results. Ciara ITV has more details.

Scientists say the first clinical trial to test whether adults - with a severe allergy to peanuts - can safely tolerate them, has had positive results. Ciara ITV has more details.

Good Morning Britain

13,411 views • 1 year ago

Boris Johnson tells an audience in Taiwan, "We will solve the problem of a shortage of social care workers which we have in the UK" "Not with more immigrants but with ChatGPT"

Boris Johnson tells an audience in Taiwan, "We will solve the problem of a shortage of social care workers which we have in the UK" "Not with more immigrants but with ChatGPT"

Farrukh

67,653 views • 11 months ago

Ketogenic diets in the ICU? The research is beginning to explore it. In a randomized controlled trial of 40 patients with sepsis, investigators tested a medically supervised ketogenic diet during critical illness. All patients in the ketogenic group achieved stable nutritional ketosis, with no serious adverse events attributed to the intervention. After day four, none of the ketogenic patients required insulin — compared to 35–60% of patients in the control group on any given day. The ketogenic group also experienced: • More ventilator-free days • More vasopressor-free days • More dialysis-free days • More ICU-free days Researchers observed signals consistent with reduced immune dysregulation and lower inflammatory signaling — a meaningful finding in a condition defined by metabolic chaos and systemic inflammation. This was a small, early-phase trial. It does not establish standard of care. But it adds to a growing body of evidence that metabolic therapy may have applications beyond chronic disease — including critical care. Check out the link below with details on how to access 150+ research summaries on metabolic health and therapy in our new Ketogenic Metabolic Therapy eBook!

Ketogenic diets in the ICU? The research is beginning to explore it. In a randomized controlled trial of 40 patients with sepsis, investigators tested a medically supervised ketogenic diet during critical illness. All patients in the ketogenic group achieved stable nutritional ketosis, with no serious adverse events attributed to the intervention. After day four, none of the ketogenic patients required insulin — compared to 35–60% of patients in the control group on any given day. The ketogenic group also experienced: • More ventilator-free days • More vasopressor-free days • More dialysis-free days • More ICU-free days Researchers observed signals consistent with reduced immune dysregulation and lower inflammatory signaling — a meaningful finding in a condition defined by metabolic chaos and systemic inflammation. This was a small, early-phase trial. It does not establish standard of care. But it adds to a growing body of evidence that metabolic therapy may have applications beyond chronic disease — including critical care. Check out the link below with details on how to access 150+ research summaries on metabolic health and therapy in our new Ketogenic Metabolic Therapy eBook!

Metabolic Health Summit

41,477 views • 4 months ago

The New England Journal of Medicine (NEJM) today published a peer-reviewed original paper with the results of a landmark clinical trial of our PRIMA brain-computer interface (BCI) retinal implant.

The New England Journal of Medicine (NEJM) today published a peer-reviewed original paper with the results of a landmark clinical trial of our PRIMA brain-computer interface (BCI) retinal implant.

Science Corporation

29,265 views • 8 months ago

An ASCO task force paper published today in ACS Journal Cancer details 3 calls-to-action for the oncology research and care communities that could expand access to clinical trials and enable patients to participate closer to home. Learn more: #OncTwitter

An ASCO task force paper published today in ACS Journal Cancer details 3 calls-to-action for the oncology research and care communities that could expand access to clinical trials and enable patients to participate closer to home. Learn more: #OncTwitter

ASCO

20,065 views • 2 years ago

In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. Full ADAPT AF-DES trial results and Research Summary:

In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. Full ADAPT AF-DES trial results and Research Summary:

NEJM

12,252 views • 4 months ago

Blank Bio (Blank Bio) is building foundation models to power a computational toolkit for RNA therapeutics, starting with mRNA design and expanding to target ID, biomarker discovery, and more. Congrats on the launch, Jonny, Phil Fradkin & Ian Shi!

Blank Bio (Blank Bio) is building foundation models to power a computational toolkit for RNA therapeutics, starting with mRNA design and expanding to target ID, biomarker discovery, and more. Congrats on the launch, Jonny, Phil Fradkin & Ian Shi!

Y Combinator

96,728 views • 11 months ago

.Strand AI builds foundation models to fill in missing patient data. They predict unmeasured biological modalities from existing ones, turning sparse clinical trial datasets into complete multimodal profiles. Congrats on the launch, עודד | oded and Yue!

.Strand AI builds foundation models to fill in missing patient data. They predict unmeasured biological modalities from existing ones, turning sparse clinical trial datasets into complete multimodal profiles. Congrats on the launch, עודד | oded and Yue!

Y Combinator

12,046 views • 4 months ago

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer.

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer.

Joe Tippens

55,953 views • 2 months ago

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer. McCullough Foundation The Wellness Company Peter A. McCullough, MD, MPH® Harvey Risch Kelly Victory MD James Thorp MD Dr. Drew Peter Gillooly Foster Coulson

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer. McCullough Foundation The Wellness Company Peter A. McCullough, MD, MPH® Harvey Risch Kelly Victory MD James Thorp MD Dr. Drew Peter Gillooly Foster Coulson

Nicolas Hulscher, MPH

761,582 views • 2 months ago

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:

NEJM

12,312 views • 2 months ago

On the ground alongside CA Fire Foundation, we got to speak with the brave firefighters and the local community in the frontlines of the recovery efforts. Together we can make a real impact. Join us in contributing to CA Fire Foundation's mission—tap our link in bio to donate today.

On the ground alongside CA Fire Foundation, we got to speak with the brave firefighters and the local community in the frontlines of the recovery efforts. Together we can make a real impact. Join us in contributing to CA Fire Foundation's mission—tap our link in bio to donate today.

Uber Eats

20,117 views • 1 year ago

When nature has a problem to solve, it makes a protein. Now, with the help of AI, what we used to have to do with electronics or optics we can increasingly do through biology. Starting with the world’s most sensitive optogenetic channels. Paper linked below ⬇️

When nature has a problem to solve, it makes a protein. Now, with the help of AI, what we used to have to do with electronics or optics we can increasingly do through biology. Starting with the world’s most sensitive optogenetic channels. Paper linked below ⬇️

Max Hodak

109,421 views • 9 months ago

Cancer reportedly DISAPPEARED or REGRESSED in nearly HALF of patients using ivermectin + mebendazole in the LARGEST real-world study to date. After just 6 months, 84.4% of cancer patients reported CLINICAL BENEFIT with these anti-parasitics. Clinical trials are now NECESSARY.

Cancer reportedly DISAPPEARED or REGRESSED in nearly HALF of patients using ivermectin + mebendazole in the LARGEST real-world study to date. After just 6 months, 84.4% of cancer patients reported CLINICAL BENEFIT with these anti-parasitics. Clinical trials are now NECESSARY.

Nicolas Hulscher, MPH

100,406 views • 2 months ago

'in the midst of so much bad news recently, i have some good news to share! so recently we heard a REALLY good song, which will be on our new album~ wait for it~'

'in the midst of so much bad news recently, i have some good news to share! so recently we heard a REALLY good song, which will be on our new album~ wait for it~'

🍒 XIAOJUN WAVES

92,424 views • 2 months ago

Today we’re releasing V-JEPA, a method for teaching machines to understand and model the physical world by watching videos. This work is another important step towards Yann LeCun’s outlined vision of AI models that use a learned understanding of the world to plan, reason and accomplish complex tasks. Details ➡️ We're releasing a collection of V-JEPA vision models trained with a feature prediction objective using self-supervised learning. The models are able to understand and predict what is going on in a video, even with limited information. It learns by predicting missing or obscured parts of a video in its internal feature space. Unlike generative approaches that fill in missing pixels, this flexible approach enables up to 6x improvements in training and sample efficiency. The models were pre-trained on entirely unlabeled data, and a small amount of labeled data can be used to train a task-specific prediction head on top after pre-training. Our results show that, using a frozen backbone, our top V-JEPA models achieve 82.0% on Kinetics-400, 72.2% on Something-Something-v2 and 77.9% on ImageNet1K — competitive with or exceeding previous leading video models. We believe that this work is an important milestone on the path to advancing machine intelligence.

Today we’re releasing V-JEPA, a method for teaching machines to understand and model the physical world by watching videos. This work is another important step towards Yann LeCun’s outlined vision of AI models that use a learned understanding of the world to plan, reason and accomplish complex tasks. Details ➡️ We're releasing a collection of V-JEPA vision models trained with a feature prediction objective using self-supervised learning. The models are able to understand and predict what is going on in a video, even with limited information. It learns by predicting missing or obscured parts of a video in its internal feature space. Unlike generative approaches that fill in missing pixels, this flexible approach enables up to 6x improvements in training and sample efficiency. The models were pre-trained on entirely unlabeled data, and a small amount of labeled data can be used to train a task-specific prediction head on top after pre-training. Our results show that, using a frozen backbone, our top V-JEPA models achieve 82.0% on Kinetics-400, 72.2% on Something-Something-v2 and 77.9% on ImageNet1K — competitive with or exceeding previous leading video models. We believe that this work is an important milestone on the path to advancing machine intelligence.

AI at Meta

703,647 views • 2 years ago

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology

Kymera Therapeutics

15,338 views • 6 months ago

An experimental gene therapy from UniQuire reduced disease progression in Huntington's patients by 75% over 36 months in a clinical trial, marking a significant milestone for the rare inherited brain disorder that has no FDA-approved treatments

An experimental gene therapy from UniQuire reduced disease progression in Huntington's patients by 75% over 36 months in a clinical trial, marking a significant milestone for the rare inherited brain disorder that has no FDA-approved treatments

Reuters

53,077 views • 9 months ago

We are preparing for new areas of cooperation with partners, such as those on drones, in order to increase our capabilities in using drones, countering Russian ones, and strengthening our electronic warfare. I also held a meeting on security guarantees, which is one of our key priorities. The related bilateral work with partners is ongoing. Today, we outlined the results we can attain in the near future.

We are preparing for new areas of cooperation with partners, such as those on drones, in order to increase our capabilities in using drones, countering Russian ones, and strengthening our electronic warfare. I also held a meeting on security guarantees, which is one of our key priorities. The related bilateral work with partners is ongoing. Today, we outlined the results we can attain in the near future.

Volodymyr Zelenskyy / Володимир Зеленський

367,183 views • 2 years ago